. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078

Table 5.

Rosiglitazone meta-analyses for heart failure

Method (fixed or random effects), and data sources	Single zero event trials	Zero total event trials	Continuity correction	Effect estimate (95% CI)	P value	No of trials
Peto (fixed)
IPD only	Included	Excluded	None	OR 1.66 (1.24 to 2.22)	0.001	26
IPD+RECORD	Included	Excluded	None	OR 1.80 (1.46 to 2.22)	0.000	27
Mantel-Haenszel (fixed)
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.60 (1.20 to 2.14)	0.002	26
IPD only	Included	Excluded		RR 1.57 (1.18 to 2.08)	0.002	27
IPD+RECORD	Included	Excluded		OR 1.78 (1.44 to 2.20)	0.000	27
IPD+RECORD	Included	Excluded		RR 1.74 (1.42 to 2.14)	0.000	27
IPD only	Included	Included		OR 1.56 (1.17 to 2.07)	0.002	33
IPD only	Included	Included		RR 1.53 (1.16 to 2.02)	0.003	33
IPD+RECORD	Included	Included		OR 1.75 (1.42 to 2.16)	0.000	34
IPD+RECORD	Included	Included		RR 1.71 (1.40 to 2.10)	0.000	34
Dersimonian and Laird (random)
IPD only	Included	Excluded	Constant continuity correction of 0.5	OR 1.54 (1.14 to 2.09)	0.005	26
IPD only	Included	Excluded		RR 1.52 (1.14 to 2.03)	0.004	26
IPD+RECORD	Included	Excluded		OR 1.75 (1.41 to 2.18)	0.000	27
IPD+RECORD	Included	Excluded		RR 1.72 (1.39 to 2.11)	0.000	27
IPD only	Included	Included		OR 1.50 (1.12 to 2.01)	0.007	33
IPD only	Included	Included		RR 1.48 (1.12 to 1.97)	0.006	33
IPD+RECORD	Included	Included		OR 1.72 (1.39 to 2.13)	0.000	34
IPD+RECORD	Included	Included		RR 1.69 (1.37 to 2.08)	0.000	34
Mantel-Haenszel (fixed)
IPD only	Included	Excluded	Treatment arm correction	OR 1.65 (1.23 to 2.20)	0.001	26
IPD only	Included	Excluded		RR 1.61 (1.21 to 2.14)	0.001	26
IPD+RECORD	Included	Excluded		OR 1.81 (1.46 to 2.24)	0.000	27
IPD+RECORD	Included	Excluded		RR 1.77 (1.44 to 2.17)	0.000	27
IPD only	Included	Included		OR 1.62 (1.21 to 2.15)	0.001	33
IPD only	Included	Included		RR 1.59 (1.20 to 2.10)	0.001	33
IPD+RECORD	Included	Included		OR 1.79 (1.45 to 2.21)	0.000	34
IPD+RECORD	Included	Included		RR 1.75 (1.42 to 2.15)	0.000	34
Dersimonian and Laird (random)
IPD only	Included	Excluded	Treatment arm correction	OR 1.58 (1.17 to 2.13)	0.003	26
IPD only	Included	Excluded		RR 1.55 (1.16 to 2.08)	0.003	26
IPD+RECORD	Included	Excluded		OR 1.77 (1.42 to 2.20)	0.000	27
IPD+RECORD	Included	Excluded		RR 1.73 (1.41 to 2.14)	0.000	27
IPD only	Included	Included		OR 1.55 (1.15 to 2.09)	0.004	33
IPD only	Included	Included		RR 1.53 (1.15 to 2.03)	0.004	33
IPD+RECORD	Included	Included		OR 1.75 (1.41 to 2.17)	0.000	34
IPD+RECORD	Included	Included		RR 1.72 (1.40 to 2.11)	0.000	34

IPD=individual patient level data; OR=odds ratio; RECORD=Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes study; RR=relative risk.

For all analyses, numbers of heart failure events observed among total population of patients was as follows: IPD only, rosiglitazone population: 122 events among 11 837 patients; IPD only, control population: 80 events among 9319 patients; RECORD, rosiglitazone population: 119 events among 2226 patients; RECORD, control population: 61 events among 2232 patients.